Ricardo Camposanto

Associate

Contact

Practice Areas

Intellectual Property

Ricardo Camposanto is an associate in Axinn’s Intellectual Property group. His practice is focused on patent litigation, including service of clients in the fields of pharmaceuticals, medical devices, and wireless technologies. In addition to his extensive trial court experience, he has also practiced before the Federal and Fourth Circuits, Patent Trial and Appeals Board, and International Trade Commission. His practice further includes counseling services related to patent portfolio evaluation, drafting of licensing agreements and other contracts, and pro bono work related to local business disputes and Section 1983 civil rights litigation.

Ricardo Camposanto

Associate

San Francisco

Contact

Practice Areas

Intellectual Property

Download PDF Download V-Card

Ricardo graduated from the University of California, Berkeley in 2009 with a BA in Molecular and Cell Biology. He received his JD from the University of Virginia School of Law, where he served on the Editorial Board for the Virginia Law Review and worked in the Appellate Litigation Clinic. In 2014, he was a judicial extern to the Honorable Margaret M. Mann with the U.S. Bankruptcy Court, Southern District of California. He worked as a summer associate at Axinn in 2015.

Experience

Alcon Inc. v. Alembic Pharmaceuticals Ltd. et al. (22-cv-00299, D. Del.). Represented Alembic Pharmaceuticals Ltd. and Alembic Pharmaceuticals Inc. in a case in which Alcon Inc. and Alcon Laboratories Inc. asserted two patents relating to Alembic’s ANDA product, an ophthalmic solution containing olopatadine hydrochloride used to treat symptoms of ocular allergies.

Cosette Pharmaceuticals Inc. v. Azurity Pharmaceuticals Inc. (23-cv-0018, D. Del.). Lead counsel to Cosette in a Hatch-Waxman suit against Azurity Pharmaceuticals Inc. involving Cosette’s vancomycin hydrochloride product. Secured total victory and consent judgment on all six asserted patents.
Salix Pharmaceuticals Ltd. et al. v. Norwich Pharmaceuticals Inc. (20-cv-00430, D. Del.). Represented Norwich Pharmaceuticals Inc. in a patent infringement action filed by Salix Pharmaceuticals Ltd., Salix Pharmaceuticals Inc., Bausch Health Ireland Ltd., and Alfasigma S.P.A. The suit sought to estop Norwich from gaining approval to market a rifaximin 550 mg tablet, a generic of Salix’s Xifaxan^®. Obtained judgment of invalidity on asserted claims, which halted the trading of plaintiff’s parent company stock after it dropped more than 50% following the decision.

Boehringer Ingelheim Pharm., Inc. et al. v. Mankind Pharma et al., No. 18-cv-689-CFC (D. Del.). Obtained favorable settlement following expert discovery in patent litigation concerning multibillion-dollar treatments for diabetes. Took and defended multiple fact and expert depositions.
iCeutica Pty Ltd. et al. v. Novitium Pharma LLC, No. 18-cv-599-CFC (D. Del.). Represented generic drug manufacturer Novitium in Hatch-Waxman litigation involving multiple patents directed to meloxicam (Vivlodex^®). Secured dismissal of case based on noninfringement position resulting in favorable settlement for Novitium. Defended depositions of two 30(b)(6) corporate witnesses. Assisted with Markman briefing and sat second-chair at related hearing. Drafted discovery requests and responses, and led meet-and-confer calls with opposing counsel.
Omeros Corp. v. Par Sterile Products, LLC, No. 15-cv-773-RGA (D. Del). Represented generic drug manufacturer, Par, in Hatch-Waxman litigation involving multiple patents directed to ketorolac tromethamine/phenylephrine HCl (Omidria^®). Secured favorable settlement for Par after three-day bench trial. Assisted with expert witness preparation, drafting of pre- and post-trial briefs, and written discovery.
Alcon Pharms. Ltd. et al. v. Par Pharm. Inc., No. 15-cv-7240 (D. N.J.). Represented generic drug manufacturer Par in Hatch-Waxman litigation involving multiple patents directed to ciprofloxacin/dexamethasone (Ciprodex^®). Secured dismissal of case based on noninfringement position resulting in favorable settlement for Par. Served second-chair in both fact and expert witness depositions, and handled written discovery disputes.
Insys Therapeutics, Inc. v. Par Pharm., Inc., No. 17-cv-01078-LPS (D. Del.). Represented generic drug manufacturer Par in Hatch-Waxman litigation involving multiple patents directed to FDA-approved cannabinoid (Syndros^®) used to treat anorexia in people with AIDS. Secured dismissal of case based on noninfringement position resulting in Par having the ability to launch upon approval of its ANDA product.
Purdue Pharma L.P. et al. v. Alvogen Pine Brook LLC, C.A. No. 15-0687-TBD (consolidated) (D. Del.). Represented Alvogen in Hatch-Waxman patent litigation action against Purdue Pharma and Grünenthal GmbH involving abuse-deterrent hydrocodone bitartrate extended-release tablets marketed as Hysingla^® ER. Case settled favorably on the eve of trial. Participated in the preparation of expert witnesses and identification of documents to support invalidity and noninfringement positions.
In re Certain UMTS and LTE Cellular Communication Modules and Products Containing the Same, No. 337-TA-1240 (ITC). Defended Thales in investigation relating to alleged infringement of cellular communications patents.

AstraZeneca AB et al. v. Alembic Pharmaceuticals Limited et al. (20-cv-202, D. Del.) Obtained a favorable settlement for Alembic in a Hatch-Waxman patent infringement action filed by AstraZeneca seeking to estop Alembic from obtaining approval to market an osimertinib oral tablet, a generic of AstraZeneca’s Tagrisso^®, for the treatment of non-small cell lung cancer.

Honors

Best Lawyers, “Ones to Watch” (2024 – 2025)
Capital Pro Bono Honor Roll (High Honors, 2023)

Education

JD – University of Virginia School of Law (2016)
BA, Molecular and Cell Biology – University of California, Berkeley (2009)

Admissions

District of Columbia
Virginia
California

Quotes

Axinn is a great mix of people who are wicked smart, hard-working and just plain nice. The firm is responsive and always comes with thoughtful approaches to problems.

Chambers USA

Profile

Experience

Alcon Inc. v. Alembic Pharmaceuticals Ltd. et al. (22-cv-00299, D. Del.). Represented Alembic Pharmaceuticals Ltd. and Alembic Pharmaceuticals Inc. in a case in which Alcon Inc. and Alcon Laboratories Inc. asserted two patents relating to Alembic’s ANDA product, an ophthalmic solution containing olopatadine hydrochloride used to treat symptoms of ocular allergies.

Cosette Pharmaceuticals Inc. v. Azurity Pharmaceuticals Inc. (23-cv-0018, D. Del.). Lead counsel to Cosette in a Hatch-Waxman suit against Azurity Pharmaceuticals Inc. involving Cosette’s vancomycin hydrochloride product. Secured total victory and consent judgment on all six asserted patents.
Salix Pharmaceuticals Ltd. et al. v. Norwich Pharmaceuticals Inc. (20-cv-00430, D. Del.). Represented Norwich Pharmaceuticals Inc. in a patent infringement action filed by Salix Pharmaceuticals Ltd., Salix Pharmaceuticals Inc., Bausch Health Ireland Ltd., and Alfasigma S.P.A. The suit sought to estop Norwich from gaining approval to market a rifaximin 550 mg tablet, a generic of Salix’s Xifaxan^®. Obtained judgment of invalidity on asserted claims, which halted the trading of plaintiff’s parent company stock after it dropped more than 50% following the decision.

Boehringer Ingelheim Pharm., Inc. et al. v. Mankind Pharma et al., No. 18-cv-689-CFC (D. Del.). Obtained favorable settlement following expert discovery in patent litigation concerning multibillion-dollar treatments for diabetes. Took and defended multiple fact and expert depositions.
iCeutica Pty Ltd. et al. v. Novitium Pharma LLC, No. 18-cv-599-CFC (D. Del.). Represented generic drug manufacturer Novitium in Hatch-Waxman litigation involving multiple patents directed to meloxicam (Vivlodex^®). Secured dismissal of case based on noninfringement position resulting in favorable settlement for Novitium. Defended depositions of two 30(b)(6) corporate witnesses. Assisted with Markman briefing and sat second-chair at related hearing. Drafted discovery requests and responses, and led meet-and-confer calls with opposing counsel.
Omeros Corp. v. Par Sterile Products, LLC, No. 15-cv-773-RGA (D. Del). Represented generic drug manufacturer, Par, in Hatch-Waxman litigation involving multiple patents directed to ketorolac tromethamine/phenylephrine HCl (Omidria^®). Secured favorable settlement for Par after three-day bench trial. Assisted with expert witness preparation, drafting of pre- and post-trial briefs, and written discovery.
Alcon Pharms. Ltd. et al. v. Par Pharm. Inc., No. 15-cv-7240 (D. N.J.). Represented generic drug manufacturer Par in Hatch-Waxman litigation involving multiple patents directed to ciprofloxacin/dexamethasone (Ciprodex^®). Secured dismissal of case based on noninfringement position resulting in favorable settlement for Par. Served second-chair in both fact and expert witness depositions, and handled written discovery disputes.
Insys Therapeutics, Inc. v. Par Pharm., Inc., No. 17-cv-01078-LPS (D. Del.). Represented generic drug manufacturer Par in Hatch-Waxman litigation involving multiple patents directed to FDA-approved cannabinoid (Syndros^®) used to treat anorexia in people with AIDS. Secured dismissal of case based on noninfringement position resulting in Par having the ability to launch upon approval of its ANDA product.
Purdue Pharma L.P. et al. v. Alvogen Pine Brook LLC, C.A. No. 15-0687-TBD (consolidated) (D. Del.). Represented Alvogen in Hatch-Waxman patent litigation action against Purdue Pharma and Grünenthal GmbH involving abuse-deterrent hydrocodone bitartrate extended-release tablets marketed as Hysingla^® ER. Case settled favorably on the eve of trial. Participated in the preparation of expert witnesses and identification of documents to support invalidity and noninfringement positions.
In re Certain UMTS and LTE Cellular Communication Modules and Products Containing the Same, No. 337-TA-1240 (ITC). Defended Thales in investigation relating to alleged infringement of cellular communications patents.

AstraZeneca AB et al. v. Alembic Pharmaceuticals Limited et al. (20-cv-202, D. Del.) Obtained a favorable settlement for Alembic in a Hatch-Waxman patent infringement action filed by AstraZeneca seeking to estop Alembic from obtaining approval to market an osimertinib oral tablet, a generic of AstraZeneca’s Tagrisso^®, for the treatment of non-small cell lung cancer.

Honors

Education

Admissions

Axinn is a great mix of people who are wicked smart, hard-working and just plain nice. The firm is responsive and always comes with thoughtful approaches to problems.

Chambers USA

Axinn is a great mix of people who are wicked smart, hard-working and just plain nice. The firm is responsive and always comes with thoughtful approaches to problems.

Chambers USA

News & Insights

View all Insights

April 24, 2025

Biosimilars Litigation and Client Counseling

Axinn partner Aziz Burgy and associates Ricardo Camposanto and Darpan Singh co-authored a chapter in the ABA Section of Intellectual Property Law publication, Biosimilars Litigation and Client Counseling.

Byline Articles

August 15, 2024

Axinn Attorneys Named to Best Lawyers 2025

Axinn is pleased to announce that eleven attorneys have been named to the 2025 list of “Best Lawyers in America” and sixteen attorneys have been named to the list of “Ones to Watch.” Two attorneys have been named “Lawyer of the Year” in their individual practice areas. Best Lawyers® compiles their lists of outstanding attorneys by conducting peer-review surveys in which tens of thousands of leading lawyers confidentially evaluate their professional peers.

Awards & Recognitions

Antitrust

May 1, 2024

Nine Axinn Attorneys Named to Capital Pro Bono Honor Roll

Nine Axinn attorneys have been named to the DC Courts 2023 Capital Pro Bono Honor Roll, which annually recognizes members of the DC Bar who performed 50 hours or more of pro bono legal services. Those who performed over 100 hours received the High Honors distinction. For 2023, 5,032 attorneys registered for the Honor Roll and the members hail from 166 firms, solo practices, federal and local government agencies, corporations, associations, and public interest organizations.

Awards & Recognitions

Antitrust

March 6, 2024

Axinn Assists Pro Bono Client with Obtaining Settlement of Civil Rights Claims

Axinn is proud to have assisted pro bono client Mayito Guzman in obtaining a favorable settlement in his civil rights claims against two California prison officials. Mr. Guzman alleged that he had been transferred on the basis of his race in violation of the U.S. Constitution’s Equal Protection Clause.

Pro Bono

August 17, 2023

Axinn Attorneys Named to Best Lawyers 2024

Axinn is pleased to announce that eleven partners have been named to the 2024 list of “Best Lawyers in America” and fifteen attorneys have been named to the list of “Ones to Watch.” Each year, Best Lawyers® partners with U.S. News & World Report, the leading rankings publication in the United States to rank law firms and attorneys across the country. Best Lawyers® compiles their lists of outstanding attorneys by conducting peer-review surveys in which tens of thousands of leading lawyers confidentially evaluate their professional peers.

Awards & Recognitions

Antitrust

August 12, 2022

Litigator of the Week Honors for Patent Trial Success

Matthew Murphy was honored in The American Lawyer’s “Litigator of the Week” column for Axinn’s trial success on behalf of Alvogen affiliate Norwich Pharmaceuticals in its defense of patent claims asserted by Bausch Health subsidiary Salix Pharmaceuticals. The column noted that the “key ruling” for Norwich, which is seeking to market a generic version of Salix’s blockbuster product Xifaxan®, led to a halt in trading of Bausch Health stock, which dropped more than 50% after news of the judge’s decision. The “Litigator of the Week” feature focuses on cases with “high stakes, long odds,” and “an impact, where the outcome matters to more than just the parties involved.”

News

Intellectual Property

August 10, 2022

Axinn Achieves Trial Success for Norwich Pharmaceuticals as it Seeks to Market a Generic of Xifaxan®

On behalf of its client Norwich Pharmaceuticals, an affiliate of Alvogen, Axinn succeeded in proving at trial that two sets of patents directed to a method of treatment (IBS-D) and composition of matter (polymorph) were invalid as obvious. Norwich is seeking approval to market a rifaximin 550 mg tablet, a generic version of Salix’s Xifaxan®, which is indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D).

News

Intellectual Property

July 6, 2022

Commission Affirms Axinn’s ITC Victory for Thales

Axinn represented Thales DIS AIS, a leading developer of cellular communication modules used in a variety of products such as CPAP machines, vehicle monitoring, wireless meters, and data terminals, in an ITC investigation that was instituted in January of 2021. Despite Thales’ efforts to negotiate a fair, reasonable, and non-discriminatory (FRAND) license, Philips filed a complaint at the ITC, seeking to exclude Thales modules from the U.S. market, asserting four patents that are allegedly essential to 3G/4G standards. Following a 5-day evidentiary hearing in October of 2021, the ALJ issued a 300+ page determination of no violation in April 2022 on multiple grounds, including findings that all of the asserted claims of the four patents asserted at the ITC are not infringed and that three of the four asserted patents are also invalid. On July 6, 2022, the Commission affirmed the determination of no violation and terminated the investigation. The Axinn team included partners Denise Plunkett, and Michael Keeley, counsel Michael O’Mara, Thomas Hedemann, and associates Chantelle Ankerman, Ramya Auroprem, Rebecca Clegg, and Ricardo Camposanto.

News

Antitrust

News & Insights

Related People

Matthew J. Becker

Intellectual Property Practice Chair

Matt Becker is the Chair of the Intellectual Property practice and has over 25 years of experience trying and litigating a diverse range of patent infringement and trade secret cases. He has tried numerous high-stakes cases to both courts and juries.

Learn more

Aziz Burgy

Partner

Experienced Hatch-Waxman Patent Litigator

As a first-chair trial attorney for major brand and generic drug companies in over 80 Hatch-Waxman Act cases, Aziz Burgy brings a wealth of experience to pharmaceutical patent litigation. Aziz has been honored among the top 3% of ANDA litigators in Patexia intelligence reports and is consistently recognized by various publications, including IAM Patent 1000, LMG Life Sciences, and Benchmark Litigation. Aziz also advises clients on FDA matters and with product selection to help clients target products for acquisition or development.

Learn more

Rebecca L. Clegg

Counsel

Rebecca Clegg's practice focuses on complex intellectual property litigation and counseling, particularly in the fields of medical devices, pharmaceuticals, biotechnology, and semiconductors. Rebecca regularly litigates medical device and Hatch-Waxman Paragraph IV patent infringement suits. She also has experience representing clients in commercial litigation cases.

Learn more